Navigation Links
CuraGen Presents Update on Clinical Development Program for,Belinostat

inically meaningful reduction in pruritus scores. As previously announced in December 2006, based on the clinical activity observed in the first phase of the study, the CTCL arm is now enrolling up to 34 patients to further refine the magnitude of the objective response rate.

In the PTCL arm, 2 of 11 evaluable patients achieved an objective response including one CR and one PR, with best responses not yet determined in 2 patients whose treatment is ongoing. CuraGen today announced that based on a recent review of this data by the Company and the study investigators, the degree of activity observed in the first phase of this study meets the predefined criteria to expand enrollment of the PTCL arm to a total of 34 patients.

"We are very encouraged by the single agent activity demonstrated in both CTCL and PTCL, and intrigued by the rapidity with which most responses are observed, an important finding given the symptomatic and debilitating nature of both diseases as well as the unmet need that exists. We look forward to further characterizing the clinical benefit patients with T-cell lymphoma can receive from treatment with intravenous belinostat," commented Dr. Francine Foss, Principal Investigator and Professor of Medical Oncology, at Yale Cancer Center.

CLN-8: Phase Ib/II trial evaluating intravenous belinostat in combination with paclitaxel and carboplatin

Phase Ib dose-escalation results on 23 patients with advanced solid tumors were presented at ASCO and indicate that the combination of intravenous belinostat plus standard doses of carboplatin and paclitaxel are generally well tolerated. Two PRs (1 pancreatic and 1 rectal cancer) were noted and one patient with mixed mullerian cancer of ovarian origin achieved an 81% reduction in CA-125 levels. In addition, 11 patients achieved stable disease (SD), including one patient with bladder cancer (SD for 20 cycles), and one patient with carcinoma of unknown primary (SD for 17 cycles and ongoi
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... that it acquired Bionik Laboratories, Inc., a ... sale to qualified accredited investors of units consisting of ... of approximately $6.2 million. Shares of the Company,s common ... Markets under the symbol "DWTPD" until FINRA,s approval of ...
(Date:2/26/2015)... 27, 2015  Finesse expands office in Leicester, ... the expansion of its operations in Leicester ... and access for customers is expected shortly afterward. ... adjacent to the current office, the new premises will ... and allow Finesse to bring on more service personnel. ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3New Finesse Office in United Kingdom 2
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... the International Symposium on Malignant Mesothelioma on Monday, March ... Hyatt Regency Bethesda in Bethesda, Maryland. The following award ... commitment to the mission to cure mesothelioma. , The ... presented to Miriam Ratner. Miriam runs the Meso Foundation’s ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
(Date:2/28/2015)... 2015 India Network Foundation, ... health insurance programs for visitors coming to the United ... parents traveling to the United States are suffering from ... blood pressure. These diseases are so common among the ... as medical conditions. There were 66.8 million cases of ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... five,disability income insurance claimants are satisfied with their ... Interactive on behalf of,America,s Health Insurance Plans (AHIP)., ... insurers are providing valuable income protection and,innovative services ... disabled,workers," said Karen Ignagni, President and CEO of ...
... developing a new type of glass that can dissolve and ... regrow bones and could signal a move away from bone ... is capable of acting as an active template for new ... of itself or any toxic chemicals. As it dissolves it ...
... ... offices, ... clinical software, connectivity and information,solutions that physicians use to improve healthcare, ... (EHR) and Practice Management (PM) solution for the 45 physicians,employed in ...
... June 5 Elekta, a world class leader ... to supply,multiple Elekta Synergy(R) digital linear accelerator systems ... few years., The new Elekta Synergy systems ... Therapy (IGRT), which Mary Bird Perkins,(MBP) began providing ...
... warns patients about injections on vacation whether ... June 5 The Physicians Coalition,for Injectable ... of the dangers of accepting Botox(R), Restylane(R) ... unfamiliar physicians during,vacation, cruise or spa encounters. ...
... chaired the committee that recently updated the ... Prevention and Treatment of Osteoporosis. The ... Organization (WHO) absolute fracture prediction algorithm (FRAX), ... identification of patients at risk for osteoporosis. ...
Cached Medicine News:Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 2Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 3Health News:A glass apart 2Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 2Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 3Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 4Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 2Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 3Health News:Botox and Restylane Not A Destination or Spa Treatment 2Health News:Botox and Restylane Not A Destination or Spa Treatment 3Health News:Botox and Restylane Not A Destination or Spa Treatment 4Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: